Please login to the form below

Not currently logged in
Email:
Password:

Zinplava

This page shows the latest Zinplava news and features for those working in and with pharma, biotech and healthcare.

Microbiome specialist Rebiotix chalks up C. diff trial success

Microbiome specialist Rebiotix chalks up C. diff trial success

Meanwhile, other emerging strategies for the prevention of C. diff recurrence include antibodies like Merck &Co's recently-approved Zinplava (bezlotoxumab) - which works by neutralising toxins secreted by the bacterium - and

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics